[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Saint-Marc O, Pozzo A, Cohen C, Le Tortorec S, Potier P, Berland B: [Gastric interdigitating reticulum cell sarcoma: unusual presentation of a histiocytic tumor]. Gastroenterol Clin Biol; 2002 May;26(5):526-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric interdigitating reticulum cell sarcoma: unusual presentation of a histiocytic tumor].
  • [Transliterated title] Sarcome gastrique à cellules interdigitées: présentation inhabituelle d'une tumeur histiocytaire rare.
  • Histiocytic sarcoma, proliferation arising from immunoregulatory effector system cells, is a very rare and recently recognized tumor.
  • Diagnosis is based on immunohistochemical and molecular genetic study, which allows to distinguish histiocytic sarcoma from lymphocytic proliferation, such as non-Hodgkin's lymphoma.
  • We report the case of a gastric interdigitating reticulum cell sarcoma, treated by resection and chemotherapy.
  • [MeSH-major] Histiocytes / pathology. Sarcoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD / analysis. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / therapeutic use. Cytarabine / therapeutic use. Diagnosis, Differential. Etoposide / therapeutic use. Gastrectomy. Humans. Immunohistochemistry. Male. Methylprednisolone / therapeutic use. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12122368.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


2. Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS: Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol; 2003 Aug;73(4):263-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
  • Febrile neutropenia (FN) is a frequent complication of cancer chemotherapy, which causes death in 4-21% of patients and worsens the quality of life of patients.
  • As a simple and accurate way of identifying patients who are at risk of FN, a lymphocyte count on post-chemotherapy day 5 was suggested.
  • From September 2001 to February 2002, patients who received cytotoxic chemotherapy at Guro Hospital, Korea University, were enrolled.
  • Blood sampling for a complete blood count was done on the starting day of chemotherapy and on day 3 and day 5 post-chemotherapy.
  • Underlying malignancies were non-Hodgkin's lymphoma (14 patients), stomach cancer (17), breast cancer (11), NSCLC (7), hepatobiliary cancer (10), sarcoma (3), colorectal cancer (3), and others (17).
  • The incidence of FN was 18% (15/82 patients), and ANC at the time of FN was 275 +/- 327/ micro l.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Fever. Lymphopenia. Neutropenia / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Incidence. Lymphocyte Count. Male. Middle Aged. Neoplasms / complications. Neoplasms / drug therapy. Predictive Value of Tests. Prospective Studies. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12879430.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Charfi S, Krichen-Makni S, Yaich S, Makni H, Khabir A, Amouri A, Charfeddine K, Hachicha J, Sellami-Boudawara T: Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment. Saudi J Kidney Dis Transpl; 2007 Nov;18(4):617-20
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment.
  • The incidence of Kaposi's sarcoma (KS) is higher in organ transplant recipients.
  • An upper gastrointestinal endoscopy revealed an ulcer in the body of the stomach.
  • Computed tomography of the chest revealed multiple bilateral lung micronodules.
  • This resulted in a regression of both stomach and pulmonary KS.
  • One-year later, the patient developed an episode of acute rejection, which was successfully treated with bolus steroids.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Kidney Transplantation / adverse effects. Lung Neoplasms / drug therapy. Sarcoma, Kaposi / drug therapy. Sirolimus / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Endoscopy, Gastrointestinal. Follow-Up Studies. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951954.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


Advertisement
4. Michiels A, Hubens G, Ruppert M, Balliu L, Vaneerdeweg W: Giant liposarcoma of the stomach involving the mediastinum. Acta Chir Belg; 2007 Jul-Aug;107(4):468-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant liposarcoma of the stomach involving the mediastinum.
  • A case of a liposarcoma of the stomach in a 27-year old woman is described.
  • MRI showed a giant tumour of the stomach wall, invading the surrounding organs, as well as the mediastinal region.
  • After surgical 'en-bloc' resection of the tumour, histopathologic examination yielded a diagnosis of pleiomorphic liposarcoma.
  • Because of the bad prognosis of this histologic type, the patient received adjuvant chemotherapy: a combination of doxorubicin and ifosfamide (MAI).
  • Palliative chemotherapy was started with the intent to prolong the young patient's life.
  • Although liposarcoma is a very common soft tissue sarcoma, it is rarely seen in the stomach.
  • The standard therapy is surgical excision.
  • Over the last years, adjuvant therapy became more accepted.
  • Drugs of choice are doxorubicin and ifosfamide, although the benefits of this therapy are still largely unknown and doubtful.
  • [MeSH-major] Liposarcoma / pathology. Mediastinum / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966553.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med; 2001 Apr 5;344(14):1052-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Fusion Proteins, bcr-abl / antagonists & inhibitors. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Sarcoma / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Female. Fluorodeoxyglucose F18. Humans. Imatinib Mesylate. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Stromal Cells. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11287975.001).
  • [ISSN] 0028-4793
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


6. Makhlouf HR, Ahrens W, Agarwal B, Dow N, Marshalleck JJ, Lee EL, Dotto JE, Hui P, Sobin LH, Oliveira A, Miettinen M: Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol; 2008 Feb;32(2):275-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases.
  • We report clinical, histopathologic, and immunohistochemical features of 10 gastric synovial sarcomas.
  • None of the patients had evidence of synovial sarcoma elsewhere.
  • Two patients had received chemotherapy after surgery, but none had postoperative radiation.
  • Two patients were alive with recurrences 6 and 48 months after diagnosis.
  • Synovial sarcoma rarely occurs as a gastric primary tumor.
  • It has a variable prognosis depending on tumor size and differentiation, and should be considered in the differential diagnosis of KIT-negative gastric spindle cell neoplasms.
  • [MeSH-major] Sarcoma, Synovial / genetics. Sarcoma, Synovial / pathology. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Combined Modality Therapy. DNA, Neoplasm. Female. Gastrectomy. Humans. Male. Middle Aged. Molecular Biology. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / analysis. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223331.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  •  go-up   go-down


7. Colovic RB, Grubor NM, Micev MT, Matic SV, Atkinson HD, Latincic SM: Perigastric extraskeletal Ewing's sarcoma: a case report. World J Gastroenterol; 2009 Jan 14;15(2):245-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perigastric extraskeletal Ewing's sarcoma: a case report.
  • Ewing's sarcoma (ES) is a neoplasm of undifferentiated small round cells, which occurs in the bones and deep soft tissues of children and adolescents.
  • We present a rare case of a 44-year-old woman with gastric ES presenting with epigastric pain and weight loss.
  • Ultrasound and computed tomography scans indicated a solid/cystic mass in the pancreatic tail.
  • At laparotomy, the tumor was found attached to the posterior surface of the stomach, completely free from the pancreas, with no lymphadenopathy or local metastases.
  • The patient had no adjuvant chemotherapy; her postoperative recovery was uneventful, and she remains symptom-free, and without any sign of recurrence at 20 mo.
  • To the best of our knowledge, this is only the third ever case of gastric ES.
  • [MeSH-major] Sarcoma, Ewing / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neuroectodermal Tumors, Primitive, Peripheral / immunology. Neuroectodermal Tumors, Primitive, Peripheral / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2000 Aug 1;25(15):1996-9 [10908947.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):753-6 [16332719.001]
  • [Cites] J R Coll Surg Edinb. 2001 Dec;46(6):372-4 [11768578.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):130-2 [11823984.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Nov;23(8):530-2 [11878783.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1040-7 [12170091.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):345-6 [12400989.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):e190-3 [12683899.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Skeletal Radiol. 1983;9(4):234-7 [6867772.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):200-4 [7911997.001]
  • [Cites] Can Assoc Radiol J. 1995 Apr;46(2):131-3 [7704678.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1125-38 [8644855.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1417-22 [9808135.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1391-400 [15618851.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jan;129(1):107-10 [15628889.001]
  • [Cites] Obstet Gynecol. 2000 Nov;96(5 Pt 2):832-4 [11094227.001]
  • (PMID = 19132777.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  • [Other-IDs] NLM/ PMC2653319
  •  go-up   go-down


8. Gambassi G, Semeraro R, Suma V, Sebastio A, Incalzi RA: Aggressive behavior of classical Kaposi's sarcoma and coexistence with angiosarcoma. J Gerontol A Biol Sci Med Sci; 2005 Apr;60(4):520-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive behavior of classical Kaposi's sarcoma and coexistence with angiosarcoma.
  • Histology allowed a diagnosis of the classical form of Kaposi's sarcoma; the serology test result for HIV was negative, whereas the associated human herpes virus type 8 was detected by polymerase chain reaction on the skin sample.
  • Chemotherapy with vinblastine appeared to stabilize the cutaneous disease, but the patient developed a massive gastrointestinal hemorrhage secondary to dissemination to the stomach.
  • Twelve months after the onset of the disease, vegetative and easily bleeding lesions progressively occluded the mouth of the patient: histological features were consistent with a low-grade angiosarcoma distinct from that of Kaposi's sarcoma.
  • This case illustrates that, even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor.
  • LEARNING POINTS: a) The extent and rate of spread of initial skin lesions should be considered to be early signs of aggressive dissemination, even in the absence of other variables (i.e., histological pattern, human herpes virus type 8 positive mononuclear cells) associated with progression of the disease.
  • c) When classical Kaposi's sarcoma displays aggressive behavior a second, primary malignant tumor arising from the vascular tissue should be investigated.
  • TAKE-HOME MESSAGE: Even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor with visceral involvement; also, a second malignancy may occur in nearly one patient of four.
  • [MeSH-major] Foot Diseases / pathology. Hemangiosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Palatal Neoplasms / pathology. Sarcoma, Kaposi / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933395.001).
  • [ISSN] 1079-5006
  • [Journal-full-title] The journals of gerontology. Series A, Biological sciences and medical sciences
  • [ISO-abbreviation] J. Gerontol. A Biol. Sci. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Duman S, Töz H, Aşçi G, Alper S, Ozkahya M, Unal I, Celik A, Ok E, Başçi A: Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant; 2002 May;17(5):892-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression.
  • BACKGROUND: The aim of this study was to investigate retrospectively the clinical presentation, the efficacy of reducing immunosuppression and the consequences of this therapeutic approach in Kaposi's sarcoma (KS) developing after renal transplantation.
  • All were on prednisone, azathioprine (AZT) and cylcosporin treatment.
  • In five patients only skin involvement was present, while the others also had visceral involvement (oropharynx in two patients, trachea and lung in three, lymph node in two, stomach and duodenum in two).
  • Cyclosporin was stopped within 1 month after KS diagnosis, and AZT was stopped in three patients.
  • Reduction or discontinuation of immunosuppression caused complete remission in all patients without surgical intervention, chemotherapy or radiotherapy.
  • [MeSH-major] Immunosuppressive Agents / administration & dosage. Kidney Transplantation / adverse effects. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / therapy. Skin Neoplasms / etiology. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981080.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


10. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Histiocytic sarcoma has the potential for an aggressive clinical course, most often with lymph node involvement.
  • [MeSH-major] Sarcoma / pathology

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ehrig T, Billings SD, Fanburg-Smith JC: Superficial primitive neuroectodermal tumor/Ewing sarcoma (PN/ES): same tumor as deep PN/ES or new entity? Ann Diagn Pathol; 2007 Jun;11(3):153-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial primitive neuroectodermal tumor/Ewing sarcoma (PN/ES): same tumor as deep PN/ES or new entity?
  • Primitive neuroectodermal tumor/Ewing sarcoma (PN/ES) is a single clinical, morphologic, and molecular small round cell tumor entity.
  • These are generally found in deep soft tissue or bone of young male patients, with poor behavior.
  • Nine cases with material for reverse transcription-polymerase chain reaction revealed 1 positive type 2 translocation (EWS exon 7 to Fli-1 exon 5), 4 negative, and 4 "unable to amplify."
  • Treatment was by wide excision; 9 received chemotherapy and 6 radiation.
  • Follow-up of 11 (85%) cases revealed the following: 1 metastasis to stomach and death at 3 years; 10 years without disease (median, 9.0 years).
  • [MeSH-major] Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Antigens, CD / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Child. Child, Preschool. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Sex Characteristics. Vimentin / genetics. Vimentin / metabolism

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498589.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Vimentin
  •  go-up   go-down


12. Steinert DM, Blakely LJ, Patel SR, Burgess MA, Chen LL, Trent JC, Raymond AK, Benjamin RS: Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):9047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy.
  • In the era of kit immunohistochemistry and imatinib mesylate therapy the outcome of IASs is unknown.
  • METHODS: We analyzed 268 consecutive patients who were referred to our institution for evaluation of the diagnosis of GIST from 12/15/00 to 9/1/01.
  • Patients diagnosed with GIST were treated with imatinib mesylate, and patients diagnosed with other IAS were treated with standard sarcoma chemotherapy.
  • A single sarcoma pathologist reviewed all patients' tumor blocks.
  • RESULTS: Of 268 patients, 4 patients were excluded because of diagnoses other than sarcoma.
  • Another 46 patients were excluded because no data were available at the time of this abstract.
  • Of the remaining 218 patients, 159 (72.9%) were GIST and 59 (27.1%) were IAS specifically: 31 leiomyosarcoma, 10 spindle cell tumors, 4 unclassified sarcomas, and 14 other types of sarcoma.
  • The most common primary tumor sites for patients with GIST were stomach (37.1%), small bowel (34%), and colon (6.3%); whereas, patients with other intra-abdominal sarcomas occurred in the retroperitoneum (25.4%), abdominal viscera (18.6%), and pelvis (11.9%).
  • While median survival from the time of diagnosis has not been reached in patients with GIST, in other IAS median survival is 63.8 months.
  • Time to progression in patients with GIST was 16.4 months after imatinib and 5.1 months in patients with IAS treated with standard sarcoma chemotherapy.
  • CONCLUSIONS: Survival and time to progression are worse for IAS compared to GISTs.
  • New therapies for these tumors are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Fléchon A, Lombard-Bohas C, Boulez J, Blay JY, Scoazec JY: Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment. Ann Oncol; 2001 Feb;12(2):275-6
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment.
  • We report the first case of an HIV negative patient with gastric Kaposi's sarcoma (KS) and peritoneal carcinomatosis in whom a complete response (CR) was obtained after liposomal daunorubicin administration.
  • Upper gastric endoscopy with multiple biopsies showed gastric involvement by KS.
  • Histological examination confirmed the diagnosis of KS with involvement of regional lymph nodes and peritoneal lesions.
  • Post-treatment coelioscopic control was normal.
  • The patient is in complete remission six months after the end of treatment.
  • Liposomal daunorubicin is a promising treatment in the non HIV patient with visceral KS.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11300338.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


14. Galbfach PJ, Langner EB, Czapiński-Tuzikiewicz T, Sroda A, Spychalski MI, Dziki AJ: [Gastrointestinal stromal tumors (GIST)]. Wiad Lek; 2007;60(3-4):114-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumors (GIST) are the example of very rare sarcoma of alimentary tract.
  • One tumor was localized in stomach, two in rectum and one in jejunum.
  • In each case confirmation of the diagnosis was done on the basis of the immunohistochemical staining--CD117(+).
  • In four cases surgery was the primary treatment.
  • One patient was disqualified from the surgical treatment.
  • Four patients were qualified for the chemotherapy with imatinib.
  • In one case, patient did not undergo the treatment.
  • On the ground of our material we conclude that patients usually begin the treatment in the advanced stage of the disease.
  • When the GIST diagnosis is probable, one has to broaden the histopathological examination with immunohistochemical staining for CD117 antigen.
  • Making the right diagnosis is crucial for patients, since imatinib is effective even in the advanced stages of the disease.
  • Nevertheless radical surgical treatment is still the primary choice for the patients with GIST.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726861.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


15. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc; 2010 May;42(4):1314-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recipients, representing an important cause of long-term morbidity and mortality.
  • METHODS: Fifteen patients developed the following malignancies at a mean of 90.3 months (range = 10-252) after kidney transplantation: metastatic gastric cancer (n = 1), metastatic colon cancer (n = 1), bilateral nephrourothelioma (n = 1), skin cancer (n = 2), Kaposi's sarcoma (n = 2), posttransplant lymphoproliferative disorder (PTLD; n = 4), renal cell carcinoma T1 (n = 1), MALT lymphoma (n = 1), intramucous colon carcinoma (n = 1), liposarcoma of the spermatic cord (n = 1).
  • After the diagnosis of malignancy, the patients were switched from calcineurin inhibitor-based immunosuppression to rapamycin (monotherapy, n = 3), or associated with steroids (n = 6) or with mycophenolate mofetil (n = 6).
  • RESULTS: Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months.
  • Two patients with PTLD who underwent chemotherapy died after 12 and 36 months.
  • Renal graft function remained stable in all other patients from diagnosis throughout follow-up.
  • Nevertheless, it is difficult to assess whether tumor regression was due to rapamycin treatment or to the reduced immunosuppression.
  • [MeSH-major] Kidney Transplantation / immunology. Neoplasms / immunology. Sirolimus / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Genital Neoplasms, Male / immunology. Genital Neoplasms, Male / pathology. Humans. Immunosuppression / methods. Immunosuppressive Agents / therapeutic use. Liposarcoma / immunology. Liposarcoma / pathology. Male. Neoplasm Metastasis. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534289.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


16. Mrad K, Morice P, Fabre A, Pautier P, Lhommé C, Duvillard P, Sabourin JC: Krukenberg tumor: a clinico-pathological study of 15 cases. Ann Pathol; 2000 May;20(3):202-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnosis of Krukenberg tumor is usually easy either on paraffin or frozen sections.
  • Two main histological types were found in our series : the classic form with sarcoma-like storiform tumoral stroma and an alternative cellular-acellular pattern.
  • Nor surgery, neither chemotherapy is efficient but bilateral oophorectomy should be proposed in post-menopausal women with gastric linitis removed surgically.
  • [MeSH-major] Breast Neoplasms / diagnosis. Colonic Neoplasms / diagnosis. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10891713.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


17. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis includes a variety of benign and malignant vascular proliferations (littoral cell angioma and Kaposi's sarcoma) as well as metastatic tumors.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


18. Schirru A, Cavaliere D, Cosce U, Scarimbolo M, Griseri G, Caristo I, Bianchi M, Ingravaglieri E, Aiello D, Venturino E: [Surgical treatment of gastrointestinal stromal tumors: personal cases]. Tumori; 2003 Jul-Aug;89(4 Suppl):141-2
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastrointestinal stromal tumors: personal cases].
  • GIST have long been a source of confusion and controversy, in particular to define their pathological classification, preoperative diagnosis, management strategies, and prognosis.
  • An effective adjuvant therapy treatment (STI571) have been found for advanced and metastatic GIST.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Chemotherapy, Adjuvant. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Disease-Free Survival. Enzyme Inhibitors / therapeutic use. Follow-Up Studies. Gastrectomy. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / surgery. Imatinib Mesylate. Jejunal Neoplasms / genetics. Jejunal Neoplasms / surgery. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Retroperitoneal Neoplasms / surgery. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903574.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 0
  •  go-up   go-down


19. Des Guetz G, De Mestier P, Pierga JY: [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)]. J Chir (Paris); 2002 Oct;139(5):268-73
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
  • [Transliterated title] Enfin un traitement efficace dans les sarcomes digestifs indifférenciés (tumeurs stromales).
  • Gastrointestinal stromal tumors (GISTs) are non differentiated sarcoma of the gastrointestinal tract and have for a long time been confused with well differentiated tumors and classified as leiomyosarcoma.
  • Recent studies have found that an inhibitor of specific tyrosine kinase is effective in the treatment of GIST with an estimated response rate of more than 60%.
  • This new drug could significantly improve the prognosis of these aggressive chemoresistant tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Benzamides. Diagnosis, Differential. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Immunohistochemistry. Leiomyosarcoma / diagnosis. Middle Aged. Mutation. Prognosis. Proto-Oncogene Proteins c-kit / genetics. Randomized Controlled Trials as Topic. Stomach / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Chir (Paris). 2002 Dec;139(6):368.
  • (PMID = 12410126.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


20. Rutkowski P, Nyckowski P, Grzesiakowska U, Nowecki ZI, Nasierowska-Guttmejer A, Pienkowski A, Dudek K, Krawczyk M, Ruka W: The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma; 2003;50(6):438-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
  • The purpose of this study was to analyze the clinical features of the group of c-KIT positive GIST patients with liver metastases evaluated and treated in two referral institutions as well as to attempt to define the role of surgery in the management of GIST given the emergence to imatinib as an important part of treatment strategy in GIST patients.
  • Of these, 35 patients (35/50; 70%) were rendered to have liver metastases and therefore offered imatinib or surgical therapy depend on CT assessment.
  • The median follow-up of these 35 patients calculated from the time of first operation was 23 months (range 3-246 months).
  • The period of time between the diagnosis of primary lesion and occurring liver metastases ranged from 0 to 164 months (median time of liver metastases presentation was 16 months for patients undergone primary curative surgery).
  • Group of 32 patients with unresectable liver involvement was considered to treatment with imatinib.
  • The median time of imatinib treatment for survivors is 7.5 months (range: 3.5-18.5 months).
  • At median follow-up 7 months, 32 of 35 patients (91.4%) were alive, 3 patients (8.6%)remained free of disease and 28 patients (87.5%) remained on imatinib treatment and have maintained disease although with partial response or stabilization only.
  • Radical surgical resection remains the only possibility of cure for GIST patients because the complete response after imatinib therapy is restricted to a few patients only.
  • However, despite the advanced metastatic disease, approximately 90% of patients are alive and continue imatinib treatment with median follow-up time more than 7 months.
  • Surgery in combination with adjuvant imatinib treatment may result in improved survival with patients with advanced GIST.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology. Liver Neoplasms / secondary. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / analysis. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Combined Modality Therapy. Female. Follow-Up Studies. Hepatectomy. Humans. Imatinib Mesylate. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology. Male. Middle Aged. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14689066.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


21. Manfredi R, Sabbatani S, Fasulo G: HIV-associated early gastric adenocarcinoma successfully cured with surgery, and followed over eight years. Int J STD AIDS; 2007 Jul;18(7):501-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated early gastric adenocarcinoma successfully cured with surgery, and followed over eight years.
  • An extremely rare case report of HIV-associated gastric adenocarcinoma surgically treated in the year 1998 in a 37-year-old male patient already HIV positive for 10 years, with a complete post-surgery disease-free follow-up of eight years, is described.
  • An international literature search allowed us to report the available details of the only nine cases of HIV-associated gastric cancer yet published.
  • Seven occurred prior to the introduction of highly active antiretroviral therapy (HAART) and were burdened by a rapid disease evolution, while only two patients were reported after the introduction of HAART (like ours) and obtained surgical cure.
  • Notably, even four of the nine published reports came from Japan, and an early disease development was usual (37-50 years of age at diagnosis).
  • Due to its relevant differential diagnosis implications with many other HIV-related gastrointestinal disturbances caused by functional and organic diseases (drug-related disturbances, HIV infection itself, opportunistic infections, and Kaposi's sarcoma and malignant lymphomas being the most frequent disorders) and the possibility of maintaining an adequate life-expectancy when diagnosis and aggressive treatment are not delayed, gastric cancer should be considered carefully by all clinicians dealing with HIV disease.
  • [MeSH-major] Adenocarcinoma / virology. Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. Stomach Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17623512.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


22. Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR: AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol; 2010 Jun 01;28(16):e250-1
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma of the gastrointestinal tract.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. Biopsy, Needle. Doxorubicin / therapeutic use. Drug Therapy, Combination. Follow-Up Studies. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / etiology. Gastrointestinal Neoplasms / pathology. HIV Infections / complications. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Severity of Illness Index. Treatment Outcome






Advertisement